Introducing SanaCurrents Introducing SanaCurrents, a research service for the serious and sophisticated biotech investor. Founder of SanaCurrents, Bill Langbein, finally brings his service to the mainstream to enable biotech investors to track catalysts through the lens of varying levels of […]
This content is for members only
Summary Trading at less than a quarter of valuation of its closest peer that was acquired by Roche in August 2014, Marina Biotech is extremely undervalued. News in the RNA therapeutics sector continues to attract strong attention; most recently in […]
There is no excerpt because this is a protected post.
22nd Century Group, Inc. (XXII) – Closed a $10 million private placement adding to dilution We will look to add to our short position. 22 days after trying to rebut our claims about the company’s share count rising, XXII Closed a $10 […]
Thermal Tennis Inc (OTCCB:TTNS) – CannaSys was originally organized as a Colorado limited liability company in October 2013 and converted to a Colorado corporation in June 2014. Based on their experience for over four years in the medical cannabis dispensary […]
Sciclone Pharmaceuticals (NASDAQ:SCLN)($6.79) – and its partner BTG plc (LSE: BTG), today announced, that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularized tumors. BTG and SciClone previously entered into […]
Call(s) to Action: XXII, DGLY, NHTC, VRYAF The GeoTeam offers it own rebuttal to XXII’s response to GeoInvesting’s article, “22nd Century Group: A Lot Of Smoke, Not Enough Fire”. We disagree with the rebuttal by XXII’s management and stand by […]